Evaluation of the real-world safety of Canakinumab in the treatment of systemic juvenile idiopathic arthritis in children aged 0–16: a comprehensive analysis based on FAERS data
This FAERS-based pharmacovigilance study provides preliminary safety data on the use of Canakinumab in children aged 0-16 years with sJIA, confirming several known adverse reactions and revealing additional potential risks. These findings offer clinicians valuable safety information for the use of Canakinumab in the treatment of sJIA.
Authors
- Xinyue Zhang (ORCID: https://orcid.org/0000-0002-4176-9516)
- Bing-qi Wei
- Chen Liu (ORCID: https://orcid.org/0000-0001-5149-2496)
- Jianjia Liu
- Yong Huang (ORCID: https://orcid.org/0009-0008-2686-8365)
- Guilong Zhang (ORCID: https://orcid.org/0000-0001-7812-8096)
- Haibin Wan (ORCID: https://orcid.org/0009-0003-3900-1967)
- Xiao Peng
- Yifan Qi (ORCID: https://orcid.org/0009-0004-9234-3226)
Institutions
- First Affiliated Hospital of Henan University (CN)
- Chengdu University of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- Pediatric Rheumatology
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1186/s12969-025-01176-2
- Citations
- 1
- Primary Topic
- Autoimmune and Inflammatory Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77